CourageAS Bio

Courage Therapeutics is a clinical-stage biotechnology company focused on developing small molecule modulators of the melanocortin 4 receptor (MC4R) to treat metabolic and neurodevelopmental disorders. The company's lead program, CT-101, is currently in Phase 1 clinical trials for the treatment of anorexia nervosa, where it acts as an MC4R antagonist to stimulate appetite and weight gain. Through its specialized subsidiary, CourageAS (also referred to as CourageAS Bio), the company is also advancing a pipeline of MC4R agonists designed to address the core symptoms of Angelman Syndrome. Courage Therapeutics leverages its deep expertise in GPCR signaling and brain circuitry to target conditions with significant unmet medical needs. The company is supported by strategic funding from the Foundation for Angelman Syndrome Therapeutics (FAST) and other private investors.